首页|诺欣妥对急性心肌梗死合并心力衰竭患者疗效及安全性观察

诺欣妥对急性心肌梗死合并心力衰竭患者疗效及安全性观察

扫码查看
目的 探究急性心肌梗死合并心力衰竭患者应用诺欣妥的疗效及安全性。方法 将本院2021年2月—2023年2月收治的98例急性心肌梗死合并心力衰竭患者纳入研究。采用盲摸双色球法分为实验组和参照组,每组49例。其中,参照组行常规治疗+依那普利,实验组给予常规治疗+诺欣妥(沙库巴曲缬沙坦片)。比较两组的心功能水平、炎症因子、不良反应发生情况。结果 实验组心功能水平中LVESD、LVEDD、LVEF及IVST水平优于参照组(P<0。05);实验组炎症因子水平中NT-pro BNP、IL-6、IL-8及TNF-α水平均低于参照组(P<0。05);两组不良反应情况比较,差异无统计学意义(P>0。05)。结论 诺欣妥能够改善急性心肌梗死合并心力衰竭患者的心功能,降低炎症因子水平及减少不良反应发生,疗效好、安全性高。
Effect and Safety Observation of Entresto for Patients with Acute Myocardial Infarction and Heart Failure
Objective To explore effect and safety of Entresto for patients with acute myocardial infarction and heart failure.Methods The paper chose 98 patients with acute myocardial infarction and heart failure in our hospital from February 2021 to February 2023 for study,and divided them into experimental group and reference group evenly with blind touch dual color sphere method,with 49 cases in each group.Reference group was treated with routine treatment with enalapril,while experimental group with routine treatment with norxintal(sacubitril valsartan tablets).Levels of cardiac function,inflammatory factors,and incidence of adverse reactions were compared between two groups.Results LVESD,LVEDD,LVEF,and IVST levels in experimental group were better than control group(P<0.05).Levels of NT pro BNP,IL-6,IL-8,and TNF-a in experimental group were lower than control group(P<0.05).Comparison of adverse reactions between two groups was(P>0.05).Conclusion Entresto can improve cardiac function of patients with acute myocardial infarction combined with heart failure,reduce levels of inflammatory factors and incidence of adverse reactions,which has good curative effect and high safety.

NoxintuoAcute myocardial infarctionHeart failureHeart functionInflammatory factorsAdverse reaction incidence

陈涛、鲁玲玲

展开 >

济南市章丘区中医医院 心血管病一科,山东 济南 250200

济南市章丘区中医医院 脊柱骨科,山东 济南 250200

诺欣妥 急性心肌梗死 心力衰竭 心功能 炎症因子 不良反应发生情况

2024

智慧健康

智慧健康

ISSN:
年,卷(期):2024.10(19)